Proceeds to build pipeline of novel fusion proteins for the treatment
of inflammatory, neuropathic and osteoarthritic pain

UTRECHT, Netherlands–(BUSINESS WIRE)–Synerkine Pharma B.V., which develops fusion proteins for the treatment
of chronic pain, announced today that it successfully closed a EUR 3.3
million Series A financing from Thuja Capital, an undisclosed private
investor, and the company’s founders.

Hans Preusting, co-founder and CEO of Synerkine Pharma, said: “We are
delighted with the closing of the Series A financing. The proceeds will
allow us to deliver a pre-clinical proof of concept in osteoarthritis
and neuropathic pain over the next two years. Our lead compound licensed
from the University Medical Center Utrecht (UMCU), a fusion protein of
IL4 and IL10, has been shown to significantly reduce chronic pain in
multiple pre-clinical models. The therapeutic potential of fusion
proteins that mimic endogenous immune molecules and are devoid of the
typical analgesic side-effects is substantial in a broad range of pain
indications.”

About Synerkine Pharma

Synerkine Pharma focuses on developing novel fusion proteins for the
treatment of inflammatory, neuropathic and osteoarthritic pain.
Synerkine Pharma was founded in 2018 and has licensed the exclusive
rights of its lead compound, a fusion protein of IL4 and IL10, from the
University Medical Center Utrecht (UMCU), the Netherlands. This fusion
protein targets common regulatory mechanisms in different types of
chronic pain, and has unique properties as demonstrated by UMCU
researchers, who showed that it is effective in reducing pain in
multiple pre-clinical models. The ability to treat pain with drugs that
mimic endogenous immune molecules and are based on a different mechanism
of action than the current anti-analgesic drugs holds tremendous
therapeutic and commercial potential.

About Thuja Capital

Thuja Capital manages several healthcare venture capital funds that
invest in private companies that aim to have a lasting impact on
patients and society. Thuja typically invests in biotech,
nutraceuticals, medtech, and digital health. The team of Thuja leverages
its deep operational, strategic and investment experience to support its
portfolio companies. For further information, visit thujacapital.com.

Contacts

Hans Preusting, PhD, MBA
Chief Executive Officer
+31 620 783
355
hans@synerkinepharma.com

Hans
Herklots
Capricorn One
+41 79 598 7149
capricorn1@bluewin.ch